HomeSRPT • NASDAQ
Sarepta Therapeutics Inc
$118.31
After Hours:
$118.31
(0.00%)0.00
Closed: Apr 15, 4:33:58 PM GMT-4 · USD · NASDAQ · Disclaimer
StockUS listed security
Previous close
$122.87
Day range
$117.78 - $122.99
Year range
$55.25 - $159.89
Market cap
11.10B USD
Avg Volume
736.53K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Financials
Income Statement
Revenue
Net income
(USD)Dec 2023Y/Y change
Revenue
396.78M53.54%
Operating expense
132.46M9.78%
Net income
45.66M141.79%
Net profit margin
11.51127.23%
Earnings per share
0.82254.72%
EBITDA
36.00M137.39%
Effective tax rate
-13.09%
Total assets
Total liabilities
(USD)Dec 2023Y/Y change
Cash and short-term investments
1.68B-15.74%
Total assets
3.26B4.35%
Total liabilities
2.41B-12.33%
Total equity
859.34M
Shares outstanding
93.86M
Price to book
13.40
Return on assets
1.93%
Return on capital
2.79%
Net change in cash
(USD)Dec 2023Y/Y change
Net income
45.66M141.79%
Cash from operations
-54.66M40.84%
Cash from investing
-64.36M-756.98%
Cash from financing
1.94M-81.92%
Net change in cash
-117.07M-62.95%
Free cash flow
-37.96M-567.82%
About
Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going public the company changed its name from AntiVirals to AVI BioPharma soon with stock symbol AVII and in July 2012 changed name from AVI BioPharma to Sarepta Therapeutics and SRPT respectively. As of 2023, the company has four approved drugs. Wikipedia
Founded
1980
Employees
1,314
Discover more
You may be interested in
This list is generated from recent searches, followed securities, and other activity. Learn more

All data and information is provided “as is” for personal informational purposes only, and is not intended to be financial advice nor is it for trading purposes or investment, tax, legal, accounting or other advice. Google is not an investment adviser nor is it a financial adviser and expresses no view, recommendation or opinion with respect to any of the companies included in this list or any securities issued by those companies. Please consult your broker or financial representative to verify pricing before executing any trades. Learn more
People also search for
Search
Clear search
Close search
Google apps
Main menu